Analysis of side effects and contraindications of sunitinib

Sunitinib is an oral multi-target tyrosine kinase inhibitor commonly used to treat malignant tumors such as renal clear cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumors (pNET). Although the drug has played a significant role in prolonging the survival of patients and controlling the disease, it is also accompanied by a series of side effects that cannot be ignored due to its broad mechanism of action and inhibition of multiple signaling pathways. Reasonably understanding the side effects and contraindication groups of sunitinib is particularly critical for safe clinical medication and patient self-management.

First of all, from the perspective of side effects, the most common adverse reactions of sunitinib include fatigue, nausea, vomiting, diarrhea, stomatitis, and hand-foot syndrome. Most side effects occur in the early stages of treatment and are dose-related reactions, among which fatigue and gastrointestinal reactions are the most common. Hand-foot syndrome is characterized by redness, swelling, tingling, and peeling of the palms or soles of the feet. If not treated properly, it may seriously affect the patient's quality of life. In addition, sunitinib may also cause serious side effects such as hypertension, thyroid dysfunction, hypocardia, and bone marrow suppression. For example, long-term use can lead to neutropenia and thrombocytopenia, and increase the risk of infection and bleeding, so routine blood indicators need to be monitored regularly during treatment.

Secondly, sunitinib may impose a certain burden on the cardiovascular system. Studies have found that the drug may cause decreased left ventricular ejection fraction, arrhythmias, and even heart failure. Patients with a history of heart disease or cardiac dysfunction need to be especially vigilant during medication. It is recommended to undergo evaluations such as electrocardiogram and cardiac ultrasound before starting treatment, and to review them regularly. If symptoms such as persistent chest tightness, palpitations, or lower limb edema occur, seek medical attention promptly. In addition, this drug may also cause bleeding tendencies, especially bleeding in the digestive tract, nasal cavity, or gums, which is more common. Close attention should be paid to coagulation function.

For certain groups of people, the use of sunitinib requires special caution and may even be contraindicated. First of all, pregnant and lactating women are strictly prohibited from using sunitinib because the drug may have teratogenic effects on the fetus, and whether it is secreted through breast milk has not yet been determined, posing potential risks. Secondly, people with severe hepatic or renal insufficiency should also use it with caution. Sunitinib is mainly metabolized by the liver, and patients with liver dysfunction may lead to drug accumulation and increased toxicity. Therefore, in such patients, the dose should be adjusted based on liver function indicators, and alternatives should even be considered.

In addition, elderly patients, those taking multiple medications, and those with a history of bleeding disorders are also high-risk groups for sunitinib. Due to reduced organ function and reduced metabolic capacity, the elderly are more likely to have adverse reactions after using this drug. A strategy of "low dose, slow onset" should be adopted and monitoring should be strengthened. For patients who are taking CYP3A4 inhibitors (such as certain antifungals, antiviral drugs) or inducers, they should also pay attention to drug interactions to avoid excessively high or low sunitinib blood concentrations affecting efficacy and safety.

In summary, as a commonly used clinical targeted therapy drug, sunitinib is effective in controlling a variety of malignant tumors, but its side effects are diverse and some are serious, which requires sufficient attention from doctors and patients. It is recommended that patients inform their doctors of their past medical history in detail before taking the medication, and conduct regular blood routine, liver and kidney function, thyroid function and heart assessments in order to detect and deal with side effects in a timely manner. At the same time, patients should pay close attention to physical changes and report abnormal symptoms to medical staff in a timely manner, so as to maximize the efficacy and minimize risks of sunitinib treatment.

Reference materials:https://www.sutent.com/